FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4366989724> ?p ?o ?g. }

• W4366989724 abstract "Zoledronic acid (ZOL) is a potent antiresorptive agent that increases bone mineral density (BMD) and reduces fracture risk in postmenopausal osteoporosis (PMOP). The anti-osteoporotic effect of ZOL is determined by annual BMD measurement. In most cases, bone turnover markers function as early indicators of therapeutic response, but they fail to reflect long-term effects. We used untargeted metabolomics to characterize time-dependent metabolic shifts in response to ZOL and to screen potential therapeutic markers. In addition, bone marrow RNA-seq was performed to support plasma metabolic profiling. Sixty rats were assigned to sham-operated group (SHAM, n = 21) and ovariectomy group (OVX, n = 39) and received sham operation or bilateral ovariectomy, respectively. After modeling and verification, rats in the OVX group were further divided into normal saline group (NS, n = 15) and ZOL group (ZA, n = 18). Three doses of 100 μg/kg ZOL were administrated to the ZA group every 2 weeks to simulate 3-year ZOL therapy in PMOP. An equal volume of saline was administered to the SHAM and NS groups. Plasma samples were collected at five time points for metabolic profiling. At the end of the study, selected rats were euthanatized for bone marrow RNA-seq. A total number of 163 compound were identified as differential metabolites between the ZA and NS groups, including mevalonate, a critical molecule in target pathway of ZOL. In addition, prolyl hydroxyproline (PHP), leucyl hydroxyproline (LHP), 4-vinylphenol sulfate (4-VPS) were identified as differential metabolites throughout the study. Moreover, 4-VPS negatively correlated with increased vertebral BMD after ZOL administration as time-series analysis revealed. Bone marrow RNA-seq showed that the PI3K-AKT signaling pathway was significantly associated with ZOL-mediated changes in expression (adjusted-p = 0.018). In conclusion, mevalonate, PHP, LHP, and 4-VPS are candidate therapeutic markers of ZOL. The pharmacological effect of ZOL likely occurs through inhibition of the PI3K-AKT signaling pathway." @default.
• W4366989724 created "2023-04-27" @default.
• W4366989724 creator A5001569082 @default.
• W4366989724 creator A5005691402 @default.
• W4366989724 creator A5009232538 @default.
• W4366989724 creator A5016501386 @default.
• W4366989724 creator A5030968272 @default.
• W4366989724 creator A5038221217 @default.
• W4366989724 creator A5055162958 @default.
• W4366989724 creator A5068061252 @default.
• W4366989724 creator A5073236619 @default.
• W4366989724 date "2023-04-25" @default.
• W4366989724 modified "2023-09-27" @default.
• W4366989724 title "Identifying therapeutic biomarkers of zoledronic acid by metabolomics" @default.
• W4366989724 cites W1501231953 @default.
• W4366989724 cites W1967103084 @default.
• W4366989724 cites W1974059464 @default.
• W4366989724 cites W1975175927 @default.
• W4366989724 cites W1981267019 @default.
• W4366989724 cites W1987003623 @default.
• W4366989724 cites W1993035292 @default.
• W4366989724 cites W2001865334 @default.
• W4366989724 cites W2005178884 @default.
• W4366989724 cites W2009341374 @default.
• W4366989724 cites W2020813947 @default.
• W4366989724 cites W2024197203 @default.
• W4366989724 cites W2041402315 @default.
• W4366989724 cites W2041762053 @default.
• W4366989724 cites W2043578305 @default.
• W4366989724 cites W2062222093 @default.
• W4366989724 cites W2071124826 @default.
• W4366989724 cites W2105602863 @default.
• W4366989724 cites W2106406207 @default.
• W4366989724 cites W2108063837 @default.
• W4366989724 cites W2123346255 @default.
• W4366989724 cites W2130007618 @default.
• W4366989724 cites W2132289378 @default.
• W4366989724 cites W2150573669 @default.
• W4366989724 cites W2156267537 @default.
• W4366989724 cites W2266084415 @default.
• W4366989724 cites W2284703075 @default.
• W4366989724 cites W2467082561 @default.
• W4366989724 cites W2614587782 @default.
• W4366989724 cites W2733907025 @default.
• W4366989724 cites W2771227656 @default.
• W4366989724 cites W2775056685 @default.
• W4366989724 cites W2795813366 @default.
• W4366989724 cites W2889069127 @default.
• W4366989724 cites W2912826725 @default.
• W4366989724 cites W2916785934 @default.
• W4366989724 cites W2963585097 @default.
• W4366989724 cites W2987788424 @default.
• W4366989724 cites W3002293416 @default.
• W4366989724 cites W3014117180 @default.
• W4366989724 cites W3014231594 @default.
• W4366989724 cites W3015654507 @default.
• W4366989724 cites W3028711203 @default.
• W4366989724 cites W3031380673 @default.
• W4366989724 cites W3042410501 @default.
• W4366989724 cites W3085671964 @default.
• W4366989724 cites W3105353438 @default.
• W4366989724 cites W3115947452 @default.
• W4366989724 cites W3140282424 @default.
• W4366989724 cites W3151294268 @default.
• W4366989724 cites W3172713090 @default.
• W4366989724 cites W3179209374 @default.
• W4366989724 cites W3184929798 @default.
• W4366989724 cites W3195883976 @default.
• W4366989724 cites W3197212851 @default.
• W4366989724 cites W3201517980 @default.
• W4366989724 cites W4206404645 @default.
• W4366989724 cites W4210365181 @default.
• W4366989724 cites W4210584888 @default.
• W4366989724 cites W4211141844 @default.
• W4366989724 cites W4211221406 @default.
• W4366989724 cites W4226458531 @default.
• W4366989724 doi "https://doi.org/10.3389/fphar.2023.1084453" @default.
• W4366989724 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37180703" @default.
• W4366989724 hasPublicationYear "2023" @default.
• W4366989724 type Work @default.
• W4366989724 citedByCount "0" @default.
• W4366989724 crossrefType "journal-article" @default.
• W4366989724 hasAuthorship W4366989724A5001569082 @default.
• W4366989724 hasAuthorship W4366989724A5005691402 @default.
• W4366989724 hasAuthorship W4366989724A5009232538 @default.
• W4366989724 hasAuthorship W4366989724A5016501386 @default.
• W4366989724 hasAuthorship W4366989724A5030968272 @default.
• W4366989724 hasAuthorship W4366989724A5038221217 @default.
• W4366989724 hasAuthorship W4366989724A5055162958 @default.
• W4366989724 hasAuthorship W4366989724A5068061252 @default.
• W4366989724 hasAuthorship W4366989724A5073236619 @default.
• W4366989724 hasBestOaLocation W43669897241 @default.
• W4366989724 hasConcept C102652120 @default.
• W4366989724 hasConcept C104317684 @default.
• W4366989724 hasConcept C126322002 @default.
• W4366989724 hasConcept C134018914 @default.
• W4366989724 hasConcept C150194340 @default.
• W4366989724 hasConcept C152724338 @default.
• W4366989724 hasConcept C170033053 @default.
• W4366989724 hasConcept C185592680 @default.

• next